Newly Diagnosed Type 2 Diabetes: Should Semaglutide Be Day-One Therapy? | Clarity of Thought Ep 5

Should a newly diagnosed patient with type 2 diabetes start semaglutide on day one? In Episode 5 of Clarity of Thought, endocrinologist Dr. Om J Lakhani is joined by Dr. Anil Bhansali — one of India's most respected endocrinologists, who trained generations of endocrinologists— to work through obesity, prediabetes and new-onset type 2 diabetes as one continuum. What you'll learn: • Why obesity, prediabetes and diabetes are one adiposity-driven disease — and why the 6.5% HbA1c cut-off shouldn't delay treatment • Lifestyle + semaglutide in prediabetes: ~84% back to normal glucose in the STEP programme • The Indian "dual defect": dual adiposity plus early beta-cell dysfunction • Day-one therapy for the obese newly diagnosed patient: metformin + semaglutide (+ SGLT2 inhibitor) • Is there still a place for metformin, sulfonylureas and pioglitazone? • The "four pillars" of liver care, and disease-modifying anti-diabetic drugs • Remission: why weight comes back after stopping, and low-dose maintenance • Red flags: when weight loss on a GLP-1RA should worry you • Tapering other drugs, protein and resistance exercise on semaglutide CHAPTERS 0:00 Welcome & introduction 1:39 The series so far & today's question 6:34 Case 1: obesity + prediabetes 9:08 Lifestyle + semaglutide as first choice 12:38 Is HbA1c 6.5% still meaningful? The continuum 15:36 Why Indians progress faster: the dual defect 20:24 Cardiovascular benefits beyond weight: SELECT 23:57 NNT 2.7 to prevent diabetes 25:20 Case 2: newly diagnosed type 2 diabetes 27:54 Day-one choice: metformin + semaglutide (+ SGLT2i) 29:14 Why every T2DM patient should get a GLP-1RA 32:03 Glucose and weight: why both matter 34:49 Is there still a role for metformin and sulfonylureas? 37:40 Pioglitazone: forgotten drug or comeback? 41:41 Four pillars of liver care 42:23 EDICT: treating from day one 44:18 Disease-modifying anti-diabetic drugs 47:34 Remission: what weight loss to target 49:17 Why weight comes back after stopping 53:29 Remission data & low-dose maintenance 55:17 Quick fire: comorbidity-driven treatment 58:23 Red flag: unexplained weight loss 59:39 Audience Q: which drugs to withdraw first 1:01:34 Audience Q: nutrition & muscle on semaglutide 1:04:50 Summary & take-home messages 1:07:33 Closing A 6-part, case-based dualogue on the real-world use of GLP-1 RAs (semaglutide) in clinical practice — Dr. Om Lakhani in conversation with a specialist each episode. • Ep 1 — GLP-1 RA & Diabetic Retinopathy • Ep 2 — Tirzepatide → Semaglutide: when to switch • Ep 3 — Semaglutide & the Heart (ASCVD) • Ep 4 — Fatty Liver: MASLD & MASH • Ep 5 — Newly Diagnosed Type 2 Diabetes (this episode) • Ep 6 — Pancreas & Gallbladder (coming next) 📝 Register free for the series, slides & recordings: https://cot.technocrinology.com Powered by Technocrinology · Unrestricted educational grant from Lupin. ⚕️ For medical professionals — educational content only, not a substitute for individualised clinical judgement or prescribing information. #Diabetes #Semaglutide #Prediabetes ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🩺 CLINICAL RESOURCES FOR PHYSICIANS & RESIDENTS • Free Clinical Notes & Algorithms (Notes in Endocrinology): https://endocrinology.co.in/ • Ask EndoAI (Clinical Endocrinology AI Assistant): https://endocrinology.co.in/endoai • Endocrinologist Toolkit & Bedside Calculators: https://endocrinology.co.in/directory • Medical AI Courses & Workflows for Doctors: https://technocrinology.com/ 🏥 PATIENT CONSULTATIONS & SECOND OPINIONS • Book Online or In-Person Appointment (AB Plus Hospital, Ahmedabad): https://consult.dromlakhani.com/ • Official Patient Portal: https://www.dromlakhani.com/ • Clinic Helpline: +91 73738 48848 👨‍⚕️ ABOUT DR. OM J. LAKHANI Consultant Endocrinologist, AB Plus Hospital, Ahmedabad & Executive Director, AIDOTE MD Medicine (Gold Medalist) | DNB Endocrinology (Sir Ganga Ram Hospital — President NBE Gold Medalist) | Specialty Certificate in Endocrinology & Diabetes (RCP, UK) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━